BioVie Inc (NASDAQ:BIVI) shares are trading higher after the drug developer announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024.

• Data from phase 2a placebo-controlled study suggest improvements in NE3107-treated patients with non-motor symptoms. 
• NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159). 
• Sleep/fatigue domain improvements correlated with motor score improvements. 
• More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.
• NMSS changes for NE3107-treated patients were driven by improvements of -0.87 in fatigue/lack of energy and improvement of -2.91 on the urge to move legs/restlessness in legs. 
• Placebo patients saw no significant change of -0.39 on fatigue (p=0.1242) and -0.71 on leg restlessness (p=0.5141).
• Furthermore, 26% of NE3107-treated patients experienced an improvement in their ability to move, having Part 3 scores before their first-morning dose of carbidopa/levodopa that were equal to or better than Part 3 scores associated with their being in the “on” state after carbidopa/levodopa treatment at the start of the study, whereas none of the placebo patients had the similarly improved morning Part 3 scores. The difference was statistically significant (p=0.046).

• The NM101 trial enrolled 439 patients through 39 sites. The company previously reported that upon trial completion, significant deviation from protocol and Good Clinical Practice violations caused the company to exclude all patients from these sites. 
• Due to the exclusion of data from many sites, the trial missed statistical significance but showed promising directional data on cognitive and functional measures. 
• NE3107-treated patients saw an advantage compared to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS, +1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL.